Metropolis Healthcare plans to achieve 14-15% revenue growth in FY27 primarily through higher patient volumes and operational efficiencies, avoiding near-term price increases. The company expects margins to improve and is expanding specialised testing and wellness services to support growth.
Metropolis Healthcare is steering towards 14% to 15% revenue growth in FY27, with management saying the expansion will be driven mainly by higher patient volumes rather than price increases. C Surendran, the company’s managing director, said Metropolis has not built in any near-term price hike and instead is counting on tighter execution, better productivity and a richer contribution from specialised testing and wellness services.
Surendran said about 9% to 10% of the target growth should come from volumes, while the rest is expected to be supported by stronger realisations from the company’s TruHealth wellness programme and specialty testing portfolio. He also said EBITDA margins are expected to improve by 100 to 150 basis points this year. In the April to June quarter, Metropolis reported revenue of ₹450 crore, net profit of ₹56 crore and a margin of 24.7%.
The guidance follows a strong FY26 finish, when Metropolis posted a 75% jump in consolidated net profit to ₹50.9 crore in the March quarter and EBITDA margin expanded to 25.43% from 18.04% a year earlier, helped by operating efficiencies and a rise in non-COVID volumes, according to recent company updates carried by Sahi. Business Standard reported that Q1 FY27 revenue rose about 16% year on year, with TruHealth Wellness and specialty testing among the fastest-growing areas, and that the company is targeting a sustainable group EBITDA margin of 27% to 28% over the next three years. The company has also highlighted Lab on Cloud as part of its growth push.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
